Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2020

01-12-2020 | Hyperparathyroidism | Research article

New parathyroid function index for the differentiation of primary and secondary hyperparathyroidism: a case-control study

Authors: Yanhong Guo, Qin Wang, Chunyan Lu, Pianpian Fan, Jing Li, Ximing Luo, Decai Chen

Published in: BMC Endocrine Disorders | Issue 1/2020

Login to get access

Abstract

Background

Patients with primary hyperparathyroidism (PHPT) may be asymptomatic, and some may present with normocalcemic PHPT (NPHPT). Patients with vitamin D deficiency may also be asymptomatic, with normal calcium and elevated PTH concentrations. These latter patients are usually diagnosed with vitamin D deficiency-induced secondary hyperparathyroidism (VD-SHPT). Therefore, it is very difficult to distinguish PHPT and NPHPT from VD-SHPT based on calcium or PTH concentrations in clinical settings. In this case-control study, we aimed to verify the diagnostic power of a new parathyroid function index (PFindex = Ca*PTH/P).

Methods

This study enrolled 128 patients with surgically and pathologically confirmed PHPT, including 36 with NPHPT, at a hospital in West China between January 2009 and September 2017. Thirty-seven patients with VD-SHPT and 45 healthy controls were selected from the population of a cross-sectional epidemiological study as the SHPT and healthy groups, respectively. We used the PFindex to describe the characteristics of PHPT, NPHPT, and VD-SHPT.. Differences between the four groups were compared, and a receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic power of PFindex.

Results

The PHPT group had the highest PFindex (454 ± 430), compared to the other three groups (NPHPT: 101 ± 111; SHPT: 21.7 ± 6.38; healthy: 12.2 ± 2.98, all p < 0.001). A PFindex cut-off value of 34 yielded sensitivity and specificity rates of 96.9 and 97.6% and of 94.4 and 94.6% for the diagnoses of PHPT and NPHPT, respectively. The use of a PFindex > 34 to differentiate NPHPT from VD-SHPT yielded the highest positive likelihood ratio and lowest negative likelihood ratio.

Conclusion

The PFindex provided excellent diagnostic power for the differentiation of NPHPT from VD-SHPT. This simple tool may be useful for guiding timely decision-making processes regarding the initiation of vitamin D treatment or surgery for PHPT.
Literature
1.
go back to reference Hoenderop JG, Nilius B, Bindels RJ. Calcium absorption across epithelia. Physiol Rev. 2005;85(1):373–422.CrossRef Hoenderop JG, Nilius B, Bindels RJ. Calcium absorption across epithelia. Physiol Rev. 2005;85(1):373–422.CrossRef
2.
go back to reference van Abel M, Hoenderop JG, van der Kemp AW, Friedlaender MM, van Leeuwen JP, Bindels RJ. Coordinated control of renal Ca (2+) transport proteins by parathyroid hormone. Kidney Int. 2005;68(4):1708–21.CrossRef van Abel M, Hoenderop JG, van der Kemp AW, Friedlaender MM, van Leeuwen JP, Bindels RJ. Coordinated control of renal Ca (2+) transport proteins by parathyroid hormone. Kidney Int. 2005;68(4):1708–21.CrossRef
3.
go back to reference Dai JC, He P, Chen X, Greenfield EM. TNFalpha and PTH utilize distinct mechanisms to induce IL-6 and RANKL expression with markedly different kinetics. Bone. 2006;38(4):509–20.CrossRef Dai JC, He P, Chen X, Greenfield EM. TNFalpha and PTH utilize distinct mechanisms to induce IL-6 and RANKL expression with markedly different kinetics. Bone. 2006;38(4):509–20.CrossRef
5.
go back to reference Eastell R, Brandi ML, Costa AG, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop [J]. J Clin Endocrinol Metab. 2009;99(10):3570–9.CrossRef Eastell R, Brandi ML, Costa AG, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop [J]. J Clin Endocrinol Metab. 2009;99(10):3570–9.CrossRef
6.
go back to reference Jayasena CN, Modi M, Palazzo F, De Silva A, Donaldson M, Meeran K, et al. Associations of serum 25-hydroxyvitamin D with circulating PTH, phosphate and calcium in patients with primary hyperparathyroidism. Clin Endocrinol. 2013;78(6):838–43.CrossRef Jayasena CN, Modi M, Palazzo F, De Silva A, Donaldson M, Meeran K, et al. Associations of serum 25-hydroxyvitamin D with circulating PTH, phosphate and calcium in patients with primary hyperparathyroidism. Clin Endocrinol. 2013;78(6):838–43.CrossRef
7.
go back to reference Souberbielle JC, Maury E, Friedlander G, Cormier C. Vitamin D and primary hyperparathyroidism (PHPT). J Steroid Biochem Mol Biol. 2010;121(1–2):199–203.CrossRef Souberbielle JC, Maury E, Friedlander G, Cormier C. Vitamin D and primary hyperparathyroidism (PHPT). J Steroid Biochem Mol Biol. 2010;121(1–2):199–203.CrossRef
8.
go back to reference Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009;94(2):351–65.CrossRef Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009;94(2):351–65.CrossRef
9.
go back to reference Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–30.CrossRef Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–30.CrossRef
10.
go back to reference Peacey SR, Wright D, Harries MJ. Failure to normalize parathyroid hormone during treatment of vitamin D deficiency in Asian patients. Clin Endocrinol. 2004;61(5):603–6.CrossRef Peacey SR, Wright D, Harries MJ. Failure to normalize parathyroid hormone during treatment of vitamin D deficiency in Asian patients. Clin Endocrinol. 2004;61(5):603–6.CrossRef
11.
go back to reference Bonjour JP, Benoit V, Payen F, Kraenzlin M. Consumption of yogurts fortified in vitamin D and calcium reduces serum parathyroid hormone and markers of bone resorption: a double-blind randomized controlled trial in institutionalized elderly women. J Clin Endocrinol Metab. 2013;98(7):2915–21.CrossRef Bonjour JP, Benoit V, Payen F, Kraenzlin M. Consumption of yogurts fortified in vitamin D and calcium reduces serum parathyroid hormone and markers of bone resorption: a double-blind randomized controlled trial in institutionalized elderly women. J Clin Endocrinol Metab. 2013;98(7):2915–21.CrossRef
12.
go back to reference Al-Azem H, Khan A. Primary hyperparathyroidism. CMAJ. 2011;183(10):E685–9.CrossRef Al-Azem H, Khan A. Primary hyperparathyroidism. CMAJ. 2011;183(10):E685–9.CrossRef
13.
go back to reference Mazeh H, Chen H, Leverson G, Sippel RS. Creation of a "Wisconsin index" nomogram to predict the likelihood of additional hyperfunctioning parathyroid glands during parathyroidectomy. Ann Surg. 2013;257(1):138–41.CrossRef Mazeh H, Chen H, Leverson G, Sippel RS. Creation of a "Wisconsin index" nomogram to predict the likelihood of additional hyperfunctioning parathyroid glands during parathyroidectomy. Ann Surg. 2013;257(1):138–41.CrossRef
14.
go back to reference Madeo B, Kara E, Cioni K, Vezzani S, Trenti T, Santi D, et al. Serum calcium to phosphorous (ca/p) ratio is a simple, inexpensive, and accurate tool in the diagnosis of primary hyperparathyroidism. JBMR Plus. 2018;2(2):109–17.CrossRef Madeo B, Kara E, Cioni K, Vezzani S, Trenti T, Santi D, et al. Serum calcium to phosphorous (ca/p) ratio is a simple, inexpensive, and accurate tool in the diagnosis of primary hyperparathyroidism. JBMR Plus. 2018;2(2):109–17.CrossRef
15.
go back to reference Wermers RA, Khosla S, Atkinson EJ, Achenbach SJ, Oberg AL, Grant CS, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res. 2006;21(1):171–7.CrossRef Wermers RA, Khosla S, Atkinson EJ, Achenbach SJ, Oberg AL, Grant CS, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res. 2006;21(1):171–7.CrossRef
16.
go back to reference Marcocci C, Cetani F. Clinical practice. Prim Hyperparathyroidism N Engl J Med. 2011;365(25):2389–97.CrossRef Marcocci C, Cetani F. Clinical practice. Prim Hyperparathyroidism N Engl J Med. 2011;365(25):2389–97.CrossRef
17.
go back to reference Zhao L, Liu JM, He XY, Zhao HY, Sun LH, Tao B, et al. The changing clinical patterns of primary hyperparathyroidism in Chinese patients: data from 2000 to 2010 in a single clinical center. J Clin Endocrinol Metab. 2013;98(2):721–8.CrossRef Zhao L, Liu JM, He XY, Zhao HY, Sun LH, Tao B, et al. The changing clinical patterns of primary hyperparathyroidism in Chinese patients: data from 2000 to 2010 in a single clinical center. J Clin Endocrinol Metab. 2013;98(2):721–8.CrossRef
18.
go back to reference Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006;81(3):353–73.CrossRef Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006;81(3):353–73.CrossRef
19.
go back to reference Shin YH, Kim KE, Lee C, Shin HJ, Kang MS, Lee HR, et al. High prevalence of vitamin D insufficiency or deficiency in young adolescents in Korea. Eur J Pediatr. 2012;171(10):1475–80.CrossRef Shin YH, Kim KE, Lee C, Shin HJ, Kang MS, Lee HR, et al. High prevalence of vitamin D insufficiency or deficiency in young adolescents in Korea. Eur J Pediatr. 2012;171(10):1475–80.CrossRef
20.
go back to reference Bilezikian JP, Khan AA, Potts JT Jr. Third international workshop on the Management of Asymptomatic Primary H. guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab. 2009;94(2):335–9.CrossRef Bilezikian JP, Khan AA, Potts JT Jr. Third international workshop on the Management of Asymptomatic Primary H. guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab. 2009;94(2):335–9.CrossRef
21.
go back to reference Wang SX, Yao Y, Zhou Y. Analysis of ecological quality of the environment and influencing factors in China during 2005–2010. Int J Environ Res Public Health. 2014 Jan;30:11(2). Wang SX, Yao Y, Zhou Y. Analysis of ecological quality of the environment and influencing factors in China during 2005–2010. Int J Environ Res Public Health. 2014 Jan;30:11(2).
22.
go back to reference Khan A, Bilezikian J. Primary hyperparathyroidism: pathophysiology and impact on bone. Can Med Assoc J. 2000;163(2):184–7. Khan A, Bilezikian J. Primary hyperparathyroidism: pathophysiology and impact on bone. Can Med Assoc J. 2000;163(2):184–7.
Metadata
Title
New parathyroid function index for the differentiation of primary and secondary hyperparathyroidism: a case-control study
Authors
Yanhong Guo
Qin Wang
Chunyan Lu
Pianpian Fan
Jing Li
Ximing Luo
Decai Chen
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2020
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-019-0487-8

Other articles of this Issue 1/2020

BMC Endocrine Disorders 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.